Insmed Reports Positive Phase 3 Results for ARIKAYCE Lung Disease Treatment

Faits marquants

1Insmed announced positive topline results from the Phase 3b ENCORE study of ARIKAYCE in patients with MAC lung disease.

2The study met primary and all multiplicity-controlled secondary endpoints, showing statistically significant improvements in respiratory symptoms and culture conversion rates.

3Insmed plans to file a supplemental NDA with the FDA and submit data to Japan's PMDA in the second half of 2026.

Insmed Incorporated (Nasdaq: INSM) shares surged nearly 8% in early Monday trading following positive topline results from its Phase 3b ENCORE clinical trial. The study specifically evaluated ARIKAYCE in treatment-naive patients newly diagnosed with MAC lung disease, comparing the drug in combination with standard multidrug therapy against a placebo group. The trial successfully met its primary endpoint and all key secondary endpoints, demonstrating statistically significant improvements in respiratory symptoms and culture conversion rates. Based on these outcomes, Insmed plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA in the second half of 2026. A similar regulatory submission is planned for Japan's PMDA during the same period to support global expansion. This milestone significantly de-risks the path toward expanded commercial potential for ARIKAYCE in the biotech market.

Inscrivez-vous gratuitement pour accéder à ce contenu

Créer un compte gratuit

Indicateurs de marché associés

Historique des versions

Version 32 minutes ago

Modifications: Added the 8% stock price increase and clarified the specific patient demographic (treatment-naive) and the control group parameters of the ENCORE trial.

Insmed Reports Positive Phase 3 Results for ARIKAYCE Lung Disease Treatment

Faits marquants

Indicateurs de marché associés

Historique des versions

Indicateurs économiques